DAL-GENE
DAL-GENE: Studies the effects on the investigated drug on Cardiovascular risk in a population with Acute Coronary Syndrome
PHASE: Enrolling
PRINCIPAL INVESTIGATOR: Mark Bieniarz, MD, FACC, FSCAI
Sub-Investigators:
Brendan Cavanaugh, MD, FACC
Raymond Yau, MD
Geoffrey Kunz, MD FACC
Charles Kim, MD, FACC
Karen Sopko, MD, FACC